Concepedia

Publication | Open Access

Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction

DOIFull Paper Access

38

Citations

24

References

2021

Year

Willem L. Bor, Kai Zheng, Anne H. Tavenier, C. Michael Gibson, Christopher B. Granger, Ohad S. Bentur, Rita Lobatto, Sonja Postma, Barry S. Coller, Arnoud W.J. van ‘t Hof,
EuroIntervention

Abstract

In patients with STEMI, a single subcutaneous dose of RUC-4 at 0.075, 0.090, and 0.110 mg/kg showed dose-response high-grade inhibition of platelet function within 15 minutes.

References

YearCitations

Page 1